BRCA1 and cancer: As the ability to predict how cells with a particular molecular make‐up (e.g. combined BRCA1/53BP1 defects) rewire in the face of a particular perturbation (e.g. Polθ inhibition) is in its infancy, only further experimentation will confirm whether a synthetic lethality that targets two combined cancer‐associated defects is less prone to resistance than those that target one defect.